TEVA vs. ICL
TEVA (Teva Pharmaceutical Industries Limited) and ICL (ICL Group Ltd) are both stocks. TEVA operates in Drug Manufacturers - Specialty & Generic (Healthcare), while ICL operates in Agricultural Inputs (Basic Materials). Over the past 10 years, TEVA returned -4.15%/yr vs 9.01%/yr for ICL. At a 0.22 correlation, their price movements are largely independent.
Performance
TEVA vs. ICL - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, TEVA achieves a 6.57% return, which is significantly higher than ICL's -0.43% return. Over the past 10 years, TEVA has underperformed ICL with an annualized return of -4.15%, while ICL has yielded a comparatively higher 9.01% annualized return.
TEVA
- 1D
- -2.72%
- 1M
- -6.91%
- YTD
- 6.57%
- 6M
- 17.40%
- 1Y
- 87.17%
- 3Y*
- 65.55%
- 5Y*
- 25.39%
- 10Y*
- -4.15%
ICL
- 1D
- -0.18%
- 1M
- -11.52%
- YTD
- -0.43%
- 6M
- 11.48%
- 1Y
- -13.76%
- 3Y*
- 3.81%
- 5Y*
- 0.16%
- 10Y*
- 9.01%
TEVA vs. ICL - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
TEVA Teva Pharmaceutical Industries Limited | 6.57% | 41.61% | 111.11% | 14.47% | 13.86% | -16.99% | -1.53% | -36.45% | -18.63% | -46.18% |
ICL ICL Group Ltd | -0.43% | 18.12% | 2.81% | -27.23% | -14.74% | 97.88% | 7.98% | -11.61% | 52.00% | 5.43% |
Correlation
The correlation between TEVA and ICL is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.08 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.17 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.25 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.22 |
Correlation (All Time) Calculated using the full available price history since Sep 25, 2014 | 0.22 |
The correlation between TEVA and ICL shifts across timeframes, from 0.08 (1 year) to 0.25 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
TEVA:
$39.21B
ICL:
$7.21B
TEVA:
$1.34
ICL:
$0.20
TEVA:
24.87
ICL:
27.66
TEVA:
0.19
ICL:
20.23
TEVA:
2.24
ICL:
0.97
TEVA:
4.76
ICL:
1.19
TEVA:
$17.35B
ICL:
$7.41B
TEVA:
$9.03B
ICL:
$2.25B
TEVA:
$3.05B
ICL:
$1.35B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
TEVA vs. ICL — Risk / Return Rank
TEVA
ICL
TEVA vs. ICL - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Teva Pharmaceutical Industries Limited (TEVA) and ICL Group Ltd (ICL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| TEVA | ICL | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.61 | ||
| Sortino ratioReturn per unit of downside risk | +3.68 | ||
| Omega ratioGain probability vs. loss probability | 1.43 | 0.97 | +0.47 |
| Calmar ratioReturn relative to maximum drawdown | 4.02 | -0.41 | +4.43 |
| Martin ratioReturn relative to average drawdown | 10.94 | -0.68 | +11.62 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| TEVA | ICL | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.25 | -0.36 | +2.61 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.59 | 0.00 | +0.59 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.09 | 0.26 | -0.35 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.31 | 0.09 | +0.22 |
Drawdowns
TEVA vs. ICL - Drawdown Comparison
The maximum TEVA drawdown since its inception was -90.89%, which is greater than ICL's maximum drawdown of -63.87%. Use the drawdown chart below to compare losses from any high point for TEVA and ICL.
Loading charts...
Drawdown Indicators
| TEVA | ICL | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -90.89% | -63.87% | -27.02% |
Max Drawdown (1Y)Largest decline over 1 year | -21.79% | -33.77% | +11.98% |
Max Drawdown (3Y)Largest decline over 3 years | -43.70% | -40.93% | -2.77% |
Max Drawdown (5Y)Largest decline over 5 years | -43.70% | -63.87% | +20.17% |
Max Drawdown (10Y)Largest decline over 10 years | -88.41% | -63.87% | -24.54% |
Current DrawdownCurrent decline from peak | -50.84% | -43.52% | -7.32% |
Average DrawdownAverage peak-to-trough decline | -32.00% | -30.37% | -1.63% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.00% | 20.33% | -12.33% |
Volatility
TEVA vs. ICL - Volatility Comparison
The current volatility for Teva Pharmaceutical Industries Limited (TEVA) is 9.18%, while ICL Group Ltd (ICL) has a volatility of 13.68%. This indicates that TEVA experiences smaller price fluctuations and is considered to be less risky than ICL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| TEVA | ICL | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.18% | 13.68% | -4.50% |
Volatility (6M)Calculated over the trailing 6-month period | 23.54% | 26.72% | -3.18% |
Volatility (1Y)Calculated over the trailing 1-year period | 38.97% | 38.27% | +0.70% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 42.94% | 37.25% | +5.69% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 47.34% | 34.73% | +12.61% |
Dividends
TEVA vs. ICL - Dividend Comparison
TEVA has not paid dividends to shareholders, while ICL's dividend yield for the trailing twelve months is around 2.64%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICL ICL Group Ltd | 2.64% | 2.29% | 3.96% | 7.34% | 16.15% | 2.58% | 1.82% | 4.45% | 6.65% | 7.23% | 4.23% | 6.73% |
TEVA Teva Pharmaceutical Industries Limited | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3.88% | 3.19% | 1.77% |
Financials
TEVA vs. ICL - Financials Comparison
This section allows you to compare key financial metrics between Teva Pharmaceutical Industries Limited and ICL Group Ltd. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
TEVA vs. ICL - Profitability Comparison
TEVA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported a gross profit of 1.97B and revenue of 3.98B. Therefore, the gross margin over that period was 49.5%.
ICL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ICL Group Ltd reported a gross profit of 626.00M and revenue of 2.02B. Therefore, the gross margin over that period was 30.9%.
TEVA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported an operating income of 652.00M and revenue of 3.98B, resulting in an operating margin of 16.4%.
ICL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ICL Group Ltd reported an operating income of 234.00M and revenue of 2.02B, resulting in an operating margin of 11.6%.
TEVA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported a net income of 369.00M and revenue of 3.98B, resulting in a net margin of 9.3%.
ICL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ICL Group Ltd reported a net income of 126.00M and revenue of 2.02B, resulting in a net margin of 6.2%.
Frequently Asked Questions
TEVA and ICL have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ICL has higher volatility (13.68%) compared to TEVA (9.18%). In terms of maximum drawdown, TEVA dropped -90.89% vs ICL's -63.87%.
TEVA currently has the higher Sharpe Ratio (2.25 vs -0.36), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for TEVA and ICL
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer